Continued double-digit growth and margin expansion
- Net revenue increased by 10 per cent to EUR 87.6m (79.9) with organic growth of 10 per cent
- Adjusted EBITA increased 20 per cent to EUR 21.9m (18.3) corresponding to a margin of 25.0 per cent (22.9)
- Operating profit (EBIT) increased 2 per cent to EUR 10.1m (9.9)
- Profit of EUR -1.9m (7.6), negatively impacted by EUR 5.0m non-realised currency impact recognised in the financial items, and earnings per share before and after dilution EUR -0.00 (0.02)
- Cash flow from operating activities of EUR 16.7m (11.6)
"We delivered another quarter with double-digit organic growth and margin expansion. Adjusted EBITA grew with 20 per cent to EUR 21.9 million, and we strengthened our cash flow from operations as we further improved our processes for inventory management. The acquisition of the global veterinary dental company iM3, completed in October, marked our entrance into a new fast-growing niche and represents a key strategic milestone for Vimian", says Patrik Eriksson, CEO of Vimian Group.
A telephone and webcast will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.
To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://conference.financialhearings.com/teleconference/?id=50047234
To attend the webcast:
Link: https://ir.financialhearings.com/vimian-group-q3-report-2024
Related presentation materials will be available on Vimian's website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.
For further information, please contact:
Maria Dahllöf Tullberg
Head of IR, Communications & Sustainability
maria.tullberg@vimian.com
+46 736 26 88 86
About Vimian
Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market's most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches over 15,000 veterinary clinics and 1,700 labs, sells to over 80 markets, has 1,100 employees and annual revenues of approximately EUR 330 million. For more information, please visit: www.vimian.com. FNCA Sweden AB is appointed the Company's Certified Adviser.
This information is information that Vimian Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-10-24 07:45 CEST.
